HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $51.
May 30, 2024 | 11:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Immunovant and maintained a price target of $51.
The reiteration of a Buy rating and a maintained price target of $51 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100